Y90 radioembolization involves placing radioactive capsules into the blood vessel feeding your tumor. It’s primarily used for cancer that can’t be treated with surgery or a liver transplant.

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed ...

March 29, 2012 (Orlando, Florida) — Results of the largest study to date assessing the efficacy of radioembolization with yttrium-90 microspheres in the treatment of unresectable hepatic tumors have ...

Bleeding events and eligibility requirements in studies evaluating an antiangiogenic agent in hepatocellular carcinoma (HCC). Background: Few effective treatments exist for unresectable hepatic ...

Radioembolization is a generally painless procedure for liver cancer that directly targets the blood supply to the tumor site. Approximately 70% to 95% of patients will experience improvements in ...

Background. A 58-year-old white man who was being followed by his hepatologist for nonalcoholic steatohepatitis-related liver cirrhosis and portal hypertension and who had been found to have a ...

The approval was based on data from the LEGACY study, a single-arm, retrospective trial that evaluated treatment with TheraSphere Y90 glass microspheres in 162 patients with unresectable ...

SIR-Spheres® Y-90 resin microspheres are now FDA-approved for unresectable HCC, marking a unique approval for both HCC and mCRC in the U.S. The DOORwaY90 study showed a 98.5% overall response rate and ...

Radioembolization (SIRT) for liver metastases Our interventional radiologists are experts in radioembolization (RAY-dee-oh-EM-boh-lih-ZAY-shun), also known as selective internal radiation therapy ...

Boston Scientific Corp.'s Therasphere Y-90 glass microspheres received a PMA for treatment of patients with unresectable hepatocellular carcinoma (HCC). The radioembolization technique has been used ...